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Figure S1.  Effect of proteasome inhibitors on different cell lines.   
(A) SH-SY5Y human neuroblastoma and NIH-3T3 mouse fibroblast cells were treated for 16 hr 
with different concentrations of bortezomib (BTZ), carfilzomib (CFZ) or MG132 as indicated. 
The whole cell lysates were immunoblotted to detect p120 and p110 forms of Nrf1. β-actin 
served as a loading control.  SH-SY5Y cells in (B) and NIH-3T3 cells in (C) were treated for 4 h 
with different concentrations of BTZ, CFZ or MG132 as indicated. HEK-293-Nrf13xFlag cells in 
(D) were treated for 1 h with CFZ.  Chymotrypsin-like (CT-like), tryspin-like (T-like) and 
caspase-like (Casp-like) activities of the 20S proteasome were measured and these values were 
normalized to cell viability and expressed as percentage of activities relative to control cells. 
Error bars denote SD (n = 3). 
  
 
Figure S2.  Processed Nrf1 can migrate to the nucleus and activate PSM gene transcription 
when proteasome is completely inactivated. 
(A) SH-SY5Y and NIH-3T3 cells were treated with CFZ for 1 h and chymotrypsin-like (CT-
like), tryspin-like (T-like) and caspase-like (Casp-like) activities of the 20S proteasome were 
measured and these values were normalized to cell viability and expressed as a percentage of 
activities relative to control cells. (B) Schematic representation of the pulse-chase experiment is 
shown. SH-SY5Y or NIH-3T3 cells were pretreated for 2 h with 10 µM NMS.  During the 
second hour, the cells were additionally exposed to 12.5 µM CFZ (which completely inhibits all 
three active sites of the proteasome). After washing out the NMS, the cells were then chased with 
12.5 µM CFZ and 100 µg/mL CHX. The cells were harvested at the sample collection points 
indicated as ‘Chase START’ and ‘Chase END’.  These samples were used to track Nrf1 by 
immunofluorescence in (C) and assess Nrf1-mediated PSM gene transcription by quantitative 
RT-PCR in (D), where NIH-3T3 cells with Nrf1 knocked out (NIH-3T3-Nrf1KO) were also 
included as a control.  Error bars denote SD (n = 3).  (E) Wild-type (NIH-3T3-WT) and Nrf1 
knockout (NIH-3T3-Nrf1KO) cell lines were treated with 5 M MG132 for 6 h.  The whole cell 
lysates were immunoblotted to detect p120 and p110 forms of Nrf1. β-actin served as a loading 
control. 
 
 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Cell culture and RNA interference 
HEK-293-Nrf13xFlag  (described in [S1]), SH-SY5Y, and NIH-3T3 cell lines were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(Atlanta Biologicals), penicillin and streptomycin (Invitrogen).  HeLa cells were cultured in 
Basal Iscove media containing 10% fetal calf serum, 2 mM L-glutamine (Biochrom, Berlin, 
Germany), 100 U/ml penicillin and 100 μg/ml streptomycin (Pan-Biotech, Aidenbach, 
Germany).  All of the above cell lines were grown at 37°C and 5% CO2 in a humidified 
atmosphere.  For RNA interference experiments, SMARTpool siRNAs were purchased from 
Dharmacon and transfected using siRNA X-treme gene reagent (Roche, Mannheim, Germany) 
according to the manufacturer's instructions. 
 
CRISPR-Cas9-mediated deletion of Nrf1 
The CRISPR construct targeting mouse Nrf1 was based on a 20-mer sequence 
(TTCCGCACCCTCGCCTGACC) present in the coding region of the gene and was cloned in to 
the lentiCRISPR v2 vector (gift from Feng Zhang; Addgene plasmid # 52961 [S2]).  The 
lentiviral supernatant produced with the CRISPR construct was used to infect NIH-3T3 cells.  
These cells were selected in puromycin to generate the Nrf1 knockout cell line (NIH-3T3-
Nrf1KO). 
 
Immunoblot analysis 
Cells treated with bortezomib, carfilzomib (L.C. Laboratories), or MG132 (Selleck Chemicals) 
were directly lysed in 1x Laemmli sample buffer followed by brief sonication to disrupt the 
viscous genomic DNA.  For Figure 1D, cells were processed for immunoblotting as described 
previously [S3].  Detection was performed using antibodies specific for TCF11/Nrf1 (8052S, 
Cell Signaling), -actin (A5441, Sigma-Aldrich), 7/PSMB4 (BML-PW8890-0025, Enzo), 
RPN10/PSMD4 (BML-PW9250-0025, Enzo), -tubulin (MMS-410P, Covance), and Ubiquitin 
(Z0458, Dako or ADI-SPA-200, Enzo). 
 
Pulse-chase assay 
HEK-293-Nrf13xFlag cells were starved for an hour in Methionine-free DMEM (Invitrogen) to 
deplete intracellular Methionine reserves.  The cells were then pre-treated for 2 h with 10 µM 
NMS-873 (Sigma-Aldrich) to accumulate Nrf1 p120.  During the second hour, the cells were 
additionally exposed to 12.5 µM carfilzomib to completely inactivate the proteasome and pulse-
labeled with 50 µM L-azidohomoalanine (Click Chemistry Tools).  NMS-873 was then washed 
out and the cells were subjected to a chase in the presence of 12.5 µM carfilzomib, 100 µg/mL 
cycloheximide (VWR) and excess of L-methionine (Sigma-Aldrich).  The cells were then 
harvested at different time points and the lysates were subjected to immunoprecipitation with 
anti-Flag beads (Sigma-Aldrich).  The resulting immunoprecipitants were labeled with Biotin-
PEG4-alkyne (Click Chemistry Tools).  Biotin-labeled species were detected by immunoblotting 
with Neutravidin-HRP (Pierce Biotechnology). 
 
Immunofluorescence microscopy 
Cells grown on coverslips were fixed and permeabilized in -20ºC methanol containing 0.1% 
triton X-100 for 10 min. Cells were washed 3 times with PBS and blocked with 2% BSA for 2 h 
followed by incubation with anti-Nrf1 antibody (8052S; Cell Signaling) for 2 h in 2% BSA at 
room temperature. The cells were then exposed to Alexa fluor 594 conjugated secondary 
antibody (A11037; Life technologies) for 1 h in 2% BSA and washed 3 times with PBS. Nuclei 
were stained with 1 mg/ml DAPI (D1306; Life Technologies) in blocking buffer for 30 min. 
Cells were then mounted using Vecta shield mounting media (Vector laboratories) and images 
were obtained using a Zeiss LSM700 confocal microscope with 63X oil immersion objective. 
 
Quantitative reverse transcription PCR 
RNA was isolated using the RNAeasy kit (Qiagen).  cDNA was prepared using the iScript kit 
(Bio-Rad) according to the manufacturer’s recommendations.  This cDNA was then subjected to 
Quantitative PCR using iTaq universal SYBR Green supermix (Bio-Rad).  The primers used to 
quantify proteasome subunits (PSM) and GAPDH mRNA levels have been described previously 
[S4]. 
 
Cellular proteasome activity assay 
Cells were subjected to freeze-thaw lysis in TE buffer (20mM Tris pH 8 and 5 mM EDTA).   
Proteasome chymotrypsin-like, trypsin-like and caspase-like activities in the lysates were 
measured using the fluorogenic peptide substrates Suc-LLVY-AMC, Boc-LRR-AMC, and Z-
LLE-AMC respectively in the presence of 0.035% SDS as described previously [S5].  These 
values were normalized to the number of viable cells as determined by the cell-titer glo 
luminescence assay (Promega). 
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